Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.

Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

CME Opportunities

Specialty

OncLive Insights

New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights

New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights

Latest Conference Coverage